清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration

耐受性 药代动力学 医学 药效学 药理学 口服 尿 不利影响 内科学
作者
Yifan Zhang,Yanmei Liu,Chen Yu,Yating Wang,Yan Zhan,Haiyan Liu,Jianjun Zou,Jingying Jia,Qian Chen,Dafang Zhong
出处
期刊:Clinical Therapeutics [Elsevier BV]
卷期号:43 (2): 396-409 被引量:14
标识
DOI:10.1016/j.clinthera.2020.12.012
摘要

Background Henagliflozin, a novel selective inhibitor of sodium–glucose cotransporter 2, is under development as a treatment for type 2 diabetes mellitus. Purpose To evaluate the tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of henagliflozin in healthy Chinese volunteers. Methods Two clinical studies were conducted. One was a single ascending dose (SAD) study (2.5–200 mg) involving 80 healthy subjects, and the other was a multiple ascending dose (MAD) study (1.25–100 mg for 10 days) involving 48 healthy subjects. The tolerability, PK profiles of henagliflozin and its main metabolites, and the urinary glucose excretion over 24 h were characterized in these 2 studies. Findings No serious adverse events were observed in the healthy subjects after single- and multiple-dose oral administration of henagliflozin, suggesting that this drug was well tolerated. Henagliflozin was rapidly absorbed, with a Tmax of 1.5–3 h, and then eliminated from plasma with a half-life of 11–15 h. It was not accumulated following once-daily oral administration. Plasma exposure of henagliflozin exhibited dose-proportional PK properties over the dose ranges of 2.5–200 mg (SAD) and 1.25–100 mg (MAD). The excretion of henagliflozin in urine was found to be very low, with 3.00%–5.13% of the dose. The glucuronide metabolites M5-1, M5-2 and M5-3 were the main metabolites detected in plasma samples, which accounted for up to 54.3%, 19.8%, and 27.5%, respectively, of the parent drug at steady state. Both the SAD and MAD studies demonstrated that the urinary glucose excretion over 24 h was dose-dependently increased and displayed saturation kinetics at >25 mg. No significant changes in the levels of serum glucose and urine electrolytes were found following a single or multiple doses of henagliflozin administration. Implications Henagliflozin was well tolerated and showed predictable PK/PD profiles in these healthy subjects. Henagliflozin did not affect blood glucose level or urinary electrolyte excretion. It is best characterized for once-daily administration with a maximum dose of 25 mg. ChinaDrugTrials.org.cn identifiers: CTR20131986 and CTR20140132.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
人鱼发布了新的文献求助10
6秒前
qqq完成签到 ,获得积分0
9秒前
Garfield完成签到 ,获得积分10
21秒前
nikki完成签到 ,获得积分10
35秒前
Maestro_S的应助被科研通管家采纳,获得10
35秒前
哈哈哈哈哈完成签到,获得积分10
39秒前
竹捷发布了新的文献求助10
47秒前
fantasy的应助被远远采纳,获得10
49秒前
蝎子莱莱xth完成签到,获得积分0
1分钟前
氢锂钠钾铷铯钫完成签到,获得积分10
1分钟前
远远完成签到,获得积分10
1分钟前
王勇1234完成签到 ,获得积分10
1分钟前
Square完成签到,获得积分10
1分钟前
林奇完成签到,获得积分10
1分钟前
abtitw完成签到,获得积分0
1分钟前
huiluowork完成签到 ,获得积分10
1分钟前
Li完成签到,获得积分10
1分钟前
Polylactic完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
旧城旧巷等旧人完成签到 ,获得积分10
2分钟前
明理芷巧完成签到,获得积分10
2分钟前
研友_LN25rL完成签到,获得积分10
2分钟前
jyy发布了新的文献求助200
2分钟前
2分钟前
fzh完成签到,获得积分10
2分钟前
Jzhaoc580完成签到 ,获得积分10
2分钟前
shangnanabcd123完成签到,获得积分10
2分钟前
太陽完成签到 ,获得积分10
2分钟前
lukehan完成签到,获得积分10
2分钟前
汉堡包的应助被Wang采纳,获得10
2分钟前
yang完成签到 ,获得积分10
3分钟前
wxm完成签到,获得积分10
3分钟前
我很厉害的1q完成签到,获得积分10
3分钟前
游泳池完成签到,获得积分10
3分钟前
饱满含玉完成签到,获得积分10
3分钟前
qianzhihe2完成签到,获得积分10
3分钟前
ninini完成签到 ,获得积分10
3分钟前
SJD完成签到,获得积分0
3分钟前
诚心金渐基完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195246
求助须知:如何正确求助?哪些是违规求助? 9580992
关于积分的说明 21873127
捐赠科研通 7795337
什么是DOI,文献DOI怎么找? 3437973
关于科研通互助平台的介绍 2561284
邀请新用户注册赠送积分活动 2484713